A research group lead by Dr. Niels Behrendt and Dr. Lars Engelholm from the Finsen Laboratory and BRIC shows that Osteosarcoma cells degrade the bone tissue through a completely different process than metastasised bone cancer. Through treatment with a specific antibody, the researchers blocked the process and reduced up to 80% of bone degradation in a cancer mouse model.